Hetal Patel, Director of Global Scientific Engagement – Interventional Oncology R&D at Johnson & Johnson, shared a post on LinkedIn:
“Join us at ECIO 2026 for a focused discussion on next‑generation intratumoral therapies and the critical role of IRs to progress in this space.
Location: Basel
Date: April 27, 9:30–10:00″
More posts on OncoDaily.